231 related articles for article (PubMed ID: 23724978)
1. Ethical use of antiretroviral resources for HIV prevention in resource poor settings.
Rennie S
Dev World Bioeth; 2013 Aug; 13(2):79-86. PubMed ID: 23724978
[TBL] [Abstract][Full Text] [Related]
2. Separate goals, converging priorities: on the ethics of treatment as prevention.
Ostmann F; Saenz C
Dev World Bioeth; 2013 Aug; 13(2):57-62. PubMed ID: 23800304
[TBL] [Abstract][Full Text] [Related]
3. From modeling to morals: imagining the future of HIV PREP in Lesotho.
Kenworthy NJ; Bulled N
Dev World Bioeth; 2013 Aug; 13(2):70-8. PubMed ID: 23800326
[TBL] [Abstract][Full Text] [Related]
4. Ethics of ARV based prevention: treatment-as-prevention and PrEP.
Haire B; Kaldor JM
Dev World Bioeth; 2013 Aug; 13(2):63-9. PubMed ID: 23594312
[TBL] [Abstract][Full Text] [Related]
5. Social justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as prevention.
Bailey TC; Sugarman J
Curr HIV Res; 2013 Sep; 11(6):473-80. PubMed ID: 24033297
[TBL] [Abstract][Full Text] [Related]
6. Anti-retrovirals for treatment and prevention--time for new paradigms in our response to the HIV/AIDS epidemic?
Abdool Karim Q; Bayer R
Dev World Bioeth; 2013 Aug; 13(2):ii-iii. PubMed ID: 23865982
[No Abstract] [Full Text] [Related]
7. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
[TBL] [Abstract][Full Text] [Related]
8. Maternal Influences on Access to and Use of Infant ARVs and HIV Health Services in Uganda.
Bergmann JN; Wanyenze RK; Makumbi F; Naigino R; Kiene SM; Stockman JK
AIDS Behav; 2017 Sep; 21(9):2693-2702. PubMed ID: 27553030
[TBL] [Abstract][Full Text] [Related]
9. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
Dao H; Mofenson LM; Ekpini R; Gilks CF; Barnhart M; Bolu O; Shaffer N
Am J Obstet Gynecol; 2007 Sep; 197(3 Suppl):S42-55. PubMed ID: 17825650
[TBL] [Abstract][Full Text] [Related]
10. Impact of new developments in antiretroviral treatment on AIDS prevention and care in resource-poor countries.
Colebunders R; Verdonck K; Nachega J; Kothari P
AIDS Patient Care STDS; 2000 May; 14(5):251-7. PubMed ID: 10833812
[TBL] [Abstract][Full Text] [Related]
11. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance.
Blower S; Ma L; Farmer P; Koenig S
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):345-53. PubMed ID: 14754434
[TBL] [Abstract][Full Text] [Related]
12. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review.
Gourlay A; Birdthistle I; Mburu G; Iorpenda K; Wringe A
J Int AIDS Soc; 2013 Jul; 16(1):18588. PubMed ID: 23870277
[TBL] [Abstract][Full Text] [Related]
13. Merging care and prevention: preventive properties of antiretroviral drugs and HIV chronification in the case of Switzerland.
Genre N; Panese F
Anthropol Med; 2022 Mar; 29(1):14-28. PubMed ID: 34544292
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a prevention of mother-to-child HIV transmission program in Guangdong province from 2007 to 2010.
Li B; Zhao Q; Zhang X; Wu L; Chen T; Liang Z; Xu L; Yu S
BMC Public Health; 2013 Jun; 13():591. PubMed ID: 23773623
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral use during pregnancy for treatment or prophylaxis.
Sturt AS; Read JS
Expert Opin Pharmacother; 2011 Aug; 12(12):1875-85. PubMed ID: 21534886
[TBL] [Abstract][Full Text] [Related]
16. The relationship between prevention of mother to child transmission of HIV and stakeholder decision making in Uganda: implications for health policy.
Kapiriri L; Robberstad B; Frithjof Norheim O
Health Policy; 2003 Nov; 66(2):199-211. PubMed ID: 14585518
[TBL] [Abstract][Full Text] [Related]
17. Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA.
Kurtz SP; Buttram ME; Surratt HL
AIDS Care; 2014 Apr; 26(4):411-5. PubMed ID: 24033118
[TBL] [Abstract][Full Text] [Related]
18. Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052.
Forsyth AD; Valdiserri RO
Curr Opin HIV AIDS; 2012 Mar; 7(2):111-6. PubMed ID: 22227586
[TBL] [Abstract][Full Text] [Related]
19. The effects of enhanced access to antiretroviral therapy: a qualitative study of community perceptions in Kampala city, Uganda.
Atuyambe L; Neema S; Otolok-Tanga E; Wamuyu-Maina G; Kasasa S; Wabwire-Mangen F
Afr Health Sci; 2008 Mar; 8(1):13-9. PubMed ID: 19357727
[TBL] [Abstract][Full Text] [Related]
20. Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention.
Gupta RK; Van de Vijver DA; Manicklal S; Wainberg MA
Retrovirology; 2013 Jul; 10():82. PubMed ID: 23902855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
